Klinik für Innere Medizin IHämatologie, Onkologie und Stammzelltransplantation

Evers M, Stühmer T, Schreder M, Steinbrunn T, Rudelius M, Jundt F, Ebert R, Hartmann TN, Bargou RC, Rosenwald A, Leich E. Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma.
Blood Cancer J. 2024 Sep 11;14(1):156. doi: 10.1038/s41408-024-01133-4.

Tissino E, Gaglio A, Nicolò A, Pozzo F, Bittolo T, Rossi FM, Bomben R, Nanni P, Cattarossi I, Zaina E, Zimbo AM, Ianna G, Capasso G, Forestieri G, Moia R, Datta M, Härzschel A, Olivieri J, D'Arena G, Laurenti L, Zaja F, Chiarenza A, Palumbo GA, Martino EA, Gentile M, Rossi D, Gaidano G, Del Poeta G, Laureana R, Del Principe MI, Maity PC, Jumaa H, Hartmann TN, Zucchetto A, Gattei V. The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
Leukemia. 2024 Aug 14. doi: 10.1038/s41375-024-02376-7. Online ahead of print. PMID: 39143370

Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, Sträng E, Kull M, Grünschläger F, Krüger J, Benary M, Müller S, Gao X, Murgai A, Haji M, Schmidt A, Lutz R, Nogai A, Braune J, Laue D, Langer C, Khandanpour C, Bassermann F, Döhner H, Engelhardt M, Straka C, Hundemer M, Beule D, Haas S, Keller U, Einsele H, Bullinger L, Knop S, Mertins P, Krönke J. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. 
Nat Cancer. 2024 Aug;5(8):1267-1284. doi: 10.1038/s43018-024-00784-3. Epub 2024 Jun 28. PMID: 38942927

Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, Staehle HF, Vinnakota JM, Duquesne S, Mozaffari Jovein M, Pfeifer D, Becker H, Blazar BR, Zähringer A, Duyster J, Brummer T, Boerries M, Baumeister J, Shoumariyeh K, Li J, Green AR, Heidel FH, Tirosh I, Pahl HL, Leimkühler N, Köhler N, de Toledo MAS, Koschmieder S, Zeiser R. Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF-β Expression and Regulatory T Cell Expansion in the Bone Marrow Microenvironment.
Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472

Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher LS, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert AL, Schramm MA, Cheng Y, Köttgen A, Duyster J, Menssen HD, Ritz J, Blazar BR, Boerries M, Schmitt Graeff A, Sariipek N, van Galen P, Buescher JM, Cabezas-Wallscheid N, Pahl HL, Pearce EL, Soiffer RJ, Wu CJ, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.
J Clin Invest. 2024 Jun 25:e177460. doi: 10.1172/JCI177460. 

Vinnakota JM, Adams RC, Athanassopoulos D, Schmidt D, Biavasco F, Zähringer A, Erny D, Schwabenland M, Langenbach M, Wenger V, Salié H, Cook J, Mossad O, Andrieux G, Dersch R, Rauer S, Duquesne S, Monaco G, Wolf P, Blank T, Häne P, Greter M, Becher B, Henneke P, Pfeifer D, Blazar BR, Duyster J, Boerries M, Köhler N, Chhatbar CM, Bengsch B, Prinz M, Zeiser R. Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation.
Science Translational Medicine 2024 Jun 12;16(751):eadj9672. doi: 10.1126/scitranslmed.adj9672. Epub 2024 Jun 12. PMID: 38865481.

Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.
Nature Cancer. 2024 May 13. doi: 10.1038/s43018-024-00764-7.
Highlighted by: Targeting TAK1 in microglia to treat CAR T  cell neurotoxicity. Nature Cancer. 2024, 5(8): 1143-1144.

Czech M*, Schneider S*, Peltokangas N*, El Khawanky N, Ghimire S, Andrieux G, Hülsdünker J, Krausz M, Proietti M, Braun LM, Rückert T, Langenbach M, Schmidt D, Martin I, Wenger V, de Vega E, Haring E, Pourjam M, Pfeifer D, Schmitt-Graeff A, Grimbacher B, Aumann K, Kircher B, Tilg H, Raffatellu M, Thiele Orberg E, Häcker G, Duyster J, Köhler N, Holler E, Nachbaur D, Boerries M, Gerner RR*, Grün D*, Zeiser R*. Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease.
Science Transl Med. 2024 Feb 21;16(735):eadi1501. doi: 10.1126/scitranslmed.adi1501. 
Highlighted by:
Markey K. Lipocalin-2: a novel therapy for GVHD. Trends in Immunology 2024

Maas-Bauer K, Stell AV, Yan KL, de Vega E, Vinnakota JM, Unger S, Núñez N, Norona J, Talvard-Balland N, Koßmann S, Schwan C, Miething C, Martens US, Shoumariyeh K, Nestor RP, Duquesne S, Hanke K, Rackiewicz M, Hu Z, El Khawanky N, Taromi S, Andrlova H, Faraidun H, Walter S, Pfeifer D, Follo M, Waldschmidt J, Melchinger W, Rassner M, Wehr C, Schmitt-Graeff A, Halbach S, Liao J, Häcker G, Brummer T, Dengjel J, Andrieux G, Grosse R, Tugues S, Blazar BR, Becher B, Boerries M, Zeiser R. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nature Commun. 2024 Jan 10;15(1):446.

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.

Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo Núñez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, Böke C, Pfeifer D, Marks R, Bertz H, Wäsch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R.

Br J Haematol. 2023 Aug 4.
DOI: 10.1111/bjh.19007. 

Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus

Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, Ioannis Ntanasis-Stathopoulos, Pieter Sonneveld & Heinz Ludwig

Leukemia. 2023 Jul 28.
DOI: 10.1038/s41375-023-01974-1.
PMID: 37507424 

Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours.

Avishai Gavish, Michael Tyler, Alissa C. Greenwald, Rouven Hoefflin, Dor Simkin, Roi Tschernichovsky, Noam Galili Darnell, Einav Somech, Chaya Barbolin, Tomer Antman, Daniel Kovarsky, Thomas Barrett, L. Nicolas Gonzalez Castro, Debdatta Halder, Rony Chanoch-Myers, Julie Laffy, Michael Mints, Adi Wider, Rotem Tal, Avishay Spitzer, Toshiro Hara, Maria Raitses-Gurevich, Chani Stossel, Talia Golan, Amit Tirosh, Mario L. Suvà, Sidharth V. Puram & Itay Tirosh

Nature. 2023 Jun;618(7965):598-606.
DOI: 10.1038/s41586-023-06130-4
PMID: 37258682

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts.

Greve G, Andrieux G, Schlosser P, Blagitko-Dorfs N, Rehman UU, Ma T, Pfeifer D, Heil G, Neubauer A, Krauter J, Heuser M, Salih HR, Döhner K, Döhner H, Hackanson B, Boerries M, Lübbert M.

Leukemia. 2023 Apr 6.
DOI: 10.1038/s41375-023-01876-2.
PMID: 37024521

Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling
and function.

Edwards-Hicks J*, Apostolova P*, Buescher JM, Maib H, Stanczak MA, Corrado M, Klein Geltink
RI, Maccari ME, Villa M, Carrizo GE, Sanin DE, Baixauli F, Kelly B, Curtis JD, Haessler F, Patterson A,
Field CS, Caputa G, Kyle RL, Soballa M, Cha M, Paul H, Martin J, Grzes KM, Flachsmann L, Mitterer
M, Zhao L, Winkler F, Rafei-Shamsabadi DA, Meiss F, Bengsch B, Zeiser R, Puleston DJ, O‘Sullivan D,
Pearce EJ, Pearce EL.

Nature Immunology 2023 Feb 2.
DOI: 10.1038/s41590-023-01419-y
* Geteilter Erstautorenschaft

Carfilzomib, lenalidomide, and dexamethasone maintenance for multiple
myeloma: when and for whom?

Engelhardt M, Wäsch R.

Lancet Oncol. 2023 Jan 12:S1470-2045(22)00792-6.
doi: 10.1016/S1470-2045(22)00792-6.
PMID: 36642082.

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

Andrea Keppler-Hafkemeyer, Christine Greil, Paul R Wratil, Khalid Shoumariyeh, Marcel Stern, Annika Hafkemeyer, Driti Ashok, Alexandra Hollaus, Gaia Lupoli, Alina Priller, Marie L Bischof, Gabriele Ihorst, Monika Engelhardt, Reinhard Marks, Jürgen Finke, Hannah Bertrand, Christopher Dächert, Maximilian Muenchhoff, Irina Badell, Florian Emmerich, Hridi Halder, Patricia M Spaeth, Percy A Knolle, Ulrike Protzer, Michael von Bergwelt-Baildon, Justus Duyster, Tanja N Hartmann, Andreas Moosmann, Oliver T Keppler
 

Nat Cancer. 2023 Jan;4(1):81-95. doi: 10.1038/s43018-022-00502-x
PMID: 36543907 PMCID: PMC9886553

Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling.

Rückert T, Andrieux G, Boerries M, Hanke-Müller K, Woessner NM, Doetsch S, Schell
C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S,
Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J,
Zeiser R, Köhler N.

Sci Transl Med. 2022 Dec 21;14(676):eabp9675. 

https://www.science.org/doi/10.1126/scitranslmed.abp9675?url_ver=Z39.88-2003&rfr_ HERAUSRAGENDE PUBLIKATION id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.

Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Núñez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, Rückert T, Märklin M, Holzmayer S, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, Köhler N, Duyster J, Menssen HD, Boerries M, Buescher JM, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce EL, Becher B, Zeiser R.

Blood. 140, 1167-1181 (2022). DOI: 10.1182/blood.2022016082

Begleitet von diesem Editorial:

MDM2 inhibition augments GVL effect.

Bleakley M, Biernacki M.

Blood. 2022 Sep 8;140(10):1064-1065. DOI: 10.1182/blood.2022017724

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.

Eliza M. Lauer*, Jurik Mutter*, and Florian Scherer.

Leukemia. 2022. doi.org/10.1038/s41375-022-01618-w

Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.

Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O'Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG.

Leukemia. 2022 Jan 13. doi: 10.1038/s41375-021-01492-y. Online ahead of print. PMID: 35027656

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial

Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CP, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJ, Meyers G, Ghosh M, Deeren D, Sanz J, Morariu-Zamfir R, Arbushites M, Lakshminarayanan M, Barbour AM, Chen YB.

Lancet Haematol. 2022 Jan; 9(1):e14-e25. doi: 10.1016/S2352-3026(21)00367-7.